MIRION

August 2, 2024

Second Quarter 2024 Earnings Presentation

MIR
LISTED
NYSE

Disclaimer

Forward-Looking Statements

This presentation and the accompanying oral commentary (this “presentation”) contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “strive”, “seeks”, “plans”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, our strategic partnership with EDF, the closure of our lasers business, macroeconomic trends, macro trends in nuclear power and cancer care, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, and our future share capitalization. There are a significant number of factors that could cause actual results to differ materially from statements made in this presentation, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict in the Middle East and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward- looking statements as a result of such risks and uncertainties. All forward-looking statements are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Basis of Presentation

As a result of the business combination (the “Business Combination”) between Mirion Technologies (TopCo), Ltd. and GS Acquisition Holdings Corp II (“GSAH”) , the Company’s financial statement presentation distinguishes Mirion TopCo as the “Predecessor” until the closing date of the Business Combination, October 20, 2021 (the “Closing Date”). Mirion Technologies, Inc. (“Mirion” or the “Company”), which includes the combination of Mirion TopCo and GSAH subsequent to the Business Combination, is the “Successor” for periods starting from the Closing Date. As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor period are presented on a full step-up basis as a result of the Business Combination, and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis due to the Business Combination.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including Organic Revenue, Adjusted Gross Profit Margin, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow, Adjusted Net Income, Adjusted Order Growth and Net Leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control or cannot be reasonably predicted. Accordingly, a reconciliation for our guidance for Organic and Inorganic Revenue Growth, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow and Net Leverage is not available without unreasonable effort.

Industry and Market Data

In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness.

Key Messages

- Raising Adjusted EBITDA guide to $195M - $205M; Reiterating 2024 organic growth guidance of 4% - 6% and Adjusted Free Cash Flow of $65M - $85M
- Signed strategic Nuclear New Build partnership agreement with EDF
- Customer engagement strong across end markets; Q2 Adjusted Order Decline of ~3% driven by timing of project orders
- Q2 Organic Revenue Growth of +3.6%; Medical +2.6% and Technologies +4.1%
- Adjusted EBITDA of $48.8M, Adjusted EBITDA margin of 23.6% - an expansion of 110-basis points
- Adjusted Free Cash Flow of $8.9M, cash flow positive for first half of the year; net leverage[1] at 3.0x
- Completed redemption of all public and private warrants and refinanced debt

1) Net Leverage defined as total net debt divided by Proforma Adjusted EBITDA. See slide 8.

Market Performance Update

End Market	1H24 Order Growth[1]	% of FY23 Revenue	Commentary and Trends
Medical	***3%***	***~36%***	
Radiation Therapy Quality Assurance (RTQA)	−	~20%	• Comping 23% order growth figure from same period last year • Accelerating improvement in domestic radiation therapy demand • Softer international orders driven by anti-corruption dynamics in China and depreciation of Japanese Yen
Dosimetry	+	~9%	• Stable market, subscription model with high recurring revenue • Formally launched Instadose VUE digital ecosystem; Strong intendant customer interest • Order timing dynamics between 2H23 and 1H24 positively impacting order growth
Nuclear Medicine	+	~7% (~9%)	• Organic order growth of ~18% in 1H24 • Growth driven by increasing use of radiopharmaceuticals and demand for molecular imaging capabilities in emerging markets
Technologies	***(3%)***	***~64%***	
Nuclear	+	+2% radiopharma[2] ~37%	• Strong installed base sustained by increased government subsidies and natural gas prices • Signed long-term exclusive partnership agreement with EDF covering all new EPR reactor projects
Defense & Diversified Industrials	±	~10%	• Booked ~$15M European Defense order at outset of Q2 • Positive outlook for global military and defense market
Labs & Research	−	~17% (~15%)	• Budgetary dynamics (DoE) impacting order timing mainly in Q1, relative improvement in Q2 • Expect order normalization to occur as the year progresses
MIRION	***(1%)***		***Nuclear Power and Cancer Care super trends driving strong customer engagement***

\+ Positive year-over-year order growth − Negative year-over-year order growth ± Flat year-over-year order growth

1) First half results through June 30; excludes reversal of $17 million MBD order booked in 2019, ec[2] acquisition and Biodex divestiture
2) 2% of revenue reflects Technologies products sold into Medical end markets. This revenue is recognized with Technologies in our year-end results, but the above adjustment moves the 2% into Medical. Note that in previous updates, this business was accounted for in the Nuclear Medicine end market.

Mirion | Second Quarter Ended June 30, 2024

Revenue
$ millions | % percentage

%	*2Q24 vs. 2Q23*
Organic	*+3.6%*
Acquisition	*+1.8%*
FX	*(0.4)%*
Total	***+5.0%***



Adjusted Gross Profit & Margin
% percentage | basis points



Adjusted EBITDA & Margin
$ millions | % percentage



Adjusted EPS
$ millions

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2023 and Q2 2024 are to the three months ended June 30, 2023 and 2024, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Medical | Second Quarter Ended June 30, 2024

Revenue

$ millions | % percentage

%	2Q24 vs. 2Q23
Organic	+2.6%
Acquisition	+5.2%
FX	(0.1)%
Total	**+7.7%**



Adjusted EBITDA and Margin

$ millions | % percentage



MEDICAL SEGMENT

Named Luis Rivera EVP of Medical business, reporting to Tom Logan, Interim Medical President

Solid top-line performance led by Nuclear Medicine

Strong margin expansion supported by software growth and procurement gains

ec^2 acquisition performing well, integration progressing better than expected

Strong execution and margin expansion in 2Q24

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2023 and Q2 2024 are to the three months ended June 30, 2023 and 2024, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Technologies | Second Quarter Ended June 30, 2024

Revenue

$ millions | % percentage

%	2Q24 vs. 2Q23
Organic	+4.1%
Acquisition	+0.0%
FX	(0.4)%
Total	**+3.7%**



Adjusted EBITDA and Margin

$ millions | % percentage



TECHNOLOGIES SEGMENT

Top-line growth driven by strong Nuclear Power demand

Signed long-term strategic Nuclear New Build partnership agreement with EDF

Solid margin expansion driven by procurement and operating leverage

Project order timing (~$30M) of two nuclear projects pushed from Q2, now expected in Q3

Solid top-line growth with strong margin expansion

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2023 and Q2 2024 are to the three months ended June 30, 2023 and 2024, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Leverage, Liquidity and Adjusted Free Cash Flow

($ millions)	1H23	1H24
Net cash provided by operating activities	**$4.4**	**$21.2**
Purchases of PPE and badges	(15.8)	(23.9)
Proceeds from derivative contracts	1.9	2.5
Cash used for non-operating expenses	4.6	4.6
Adjusted free cash flow	**$(4.9)**	**$4.4**
Ending cash balance	$87	$122
Debt from first lien term loan	695	695
Net Debt	**$608**	**$573**
LTM Adjusted EBITDA	168	188
LTM Adjusted EBITDA Contribution from M&A[1]	0	2
LTM Adjusted EBITDA Plus M&A Contribution	**$168**	**$190**
Total net debt / M&A Adjusted EBITDA (Net Leverage)	**3.6x**	**3.0x**

- Adjusted free cash flow of $8.9M in 2Q24 compared to $2.3M in 2Q23
- Capex higher year-over-year, driven by one-time Instadose VUE launch investment
- Trending year-over-year improvements in inventory and accounts receivable metrics, as well as net working capital days, offset by project cash flow timing
- Inventory management and turnover improvement remains largest point of emphasis for net working capital enhancement
- Continue to work to reduce below the line cash expense items

Committed to Driving Net Working Capital and Improved Cash Conversion

1) Reflects Adjusted EBITDA contribution from ec^2 if ec^2 had been acquired before the start of the LTM period.
References to 1H23 and 1H24 are to the six months ended June 30, 2023 and 2024, respectively.

Updated Guidance for 2024

Category[1]	August 2, 2024	May 1, 2024	What we are seeing and expectations
Revenue Growth **Organic Revenue Growth[2]**	*No Change*	***5% to 7%*** ***4% to 6%***	• Net inorganic growth expected to be ~1.5% from ec[2] acquisition • Expected shutdown of lasers business projected to impact organic growth by ~30 bps
Adjusted EBITDA *Margin %[3]*	**$195M to $205M** *23% to 24%*	**$193M to $203M** *23% to 24%*	• Adjusted EBITDA margin expansion driven by pricing and procurement initiatives, higher recurring volume and positive margin/mix
Adjusted EPS	No Change	**$0.37 to $0.42**	• Depreciation of ~$34M for the year • Net interest expense of ~$53M • Effective tax rate between 27% and 29%
Adjusted FCF	No Change	**$65M to $85M**	• NWC target is a source of cash at mid-point • Capex of ~$42M • Net cash interest of ~$52M • Cash taxes of ~$35M

End Market/Segment	'24 Organic Rev Growth Est
Radiation Therapy Quality Assurance	LSD
Dosimetry	LSD+
Nuclear Medicine	HSD
Medical	**LSD+**
Nuclear	MSD+
Defense & Diversified Industrials	LSD
Labs & Research	MSD
Technologies	**MSD+**
Total Mirion	**4% to 6%**

Other modelling assumptions:

- Shares for Adjusted EPS calculation of ~205M[4]
- USD to EUR FX Rate of 1.07
- Cash non-operating expenses of ~$10M
- Stock-based compensation of ~$11M

Note: Guidance as of August 2, 2024.

1) For a reconciliation of adjusted metrics to the most directly comparable GAAP measures, please see the Appendix.
2) Revenue Growth includes the impacts of foreign exchange and acquisitions. Organic revenue growth excludes the impacts of foreign exchange, mergers, acquisitions and divestitures.
3) Adjusted EBITDA as a percentage of revenue.
4) As of June 30, 2024, 206.6 million shares of Class A common stock outstanding (excludes 6.9 million shares of Class B common stock, 18.8 million founder shares, subject to vesting, 1.8 million restricted stock units, 1.2 million performance stock units and a further 34.4 million shares reserved for future equity awards under our 2021 Omnibus Incentive Plan (subject to annual increase)). See the Appendix for more information.

Appendix

Backlog Trend | 2Q22 – 2Q24



Note: Backlog figures on an as reported basis.
Backlog figures include acquisitions of SIS after Sep-22 and ec[2] after Dec-23.

2-Year Revenue Growth Stacks

Total Company

Organic Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	5.5%	3.6%			
b	2023	7.9%	8.4%	17.3%	5.3%	9.3%
c	2022	(4.2)%	(1.7)%	9.0%	19.1%	5.7%
a+b=d	2-Yr Stack 2024	13.4%	12.0%			
b+c=e	2-Yr Stack 2023	3.7%	6.7%	26.3%	24.4%	15.0%

Reported Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	5.8%	5.0%			
b	2023	11.6%	12.2%	18.8%	5.7%	11.6%
c	2022	(4.3)%	(4.3)%	8.7%	20.5%	5.3%
a+b=d	2-Yr Stack 2024	17.4%	17.2%			
b+c=e	2-Yr Stack 2023	7.3%	7.9%	27.5%	26.2%	16.9%

Medical

Organic Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	0.6%	2.6%			
b	2023	10.8%	6.9%	5.2%	9.6%	8.1%
c	2022	0.7%	15.1%	20.7%	23.6%	15.2%
a+b=d	2-Yr Stack 2024	11.4%	9.5%			
b+c=e	2-Yr Stack 2023	11.5%	22.0%	25.9%	33.2%	23.3%

Reported Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	0.6%	7.7%			
b	2023	10.5%	1.8%	0.1%	6.8%	4.7%
c	2022	7.7%	19.6%	23.3%	25.4%	19.2%
a+b=d	2-Yr Stack 2024	11.1%	9.5%			
b+c=e	2-Yr Stack 2023	18.2%	21.4%	23.4%	32.2%	23.9%

Technologies

Organic Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	8.4%	4.1%			
b	2023	6.1%	9.3%	26.3%	3.0%	10.1%
c	2022	(6.6)%	(9.0)%	2.0%	16.8%	0.9%
a+b=d	2-Yr Stack 2024	14.5%	13.4%			
b+c=e	2-Yr Stack 2023	(0.5)%	0.3%	28.3%	19.8%	11.0%

Reported Revenue Growth

		Q1	Q2	Q3	Q4	FY
a	2024	8.7%	3.7%			
b	2023	12.2%	18.5%	32.8%	5.1%	15.8%
c	2022	(10.2)%	(14.7)%	(0.1)%	17.9%	(1.7)%
a+b=d	2-Yr Stack 2024	20.9%	22.2%			
b+c=e	2-Yr Stack 2023	2.0%	3.8%	32.7%	23.0%	14.1%

Note: See following slides, including the ten-quarter segment reconciliation, for a reconciliation to revenue

Ten Quarter Segment Reconciliation

Medical

	Successor									
($ in millions)	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	**$ 73.2**	**$ 66.8**	**$ 81.3**	**$ 68.8**	**$ 68.0**	**$ 66.4**	**$ 76.1**	**$ 68.7**	**$ 66.8**	**$ 60.1**
YoY % Growth - Total	*7.7 %*	*0.6 %*	*6.8 %*	*0.1 %*	*1.8 %*	*10.5 %*	*25.4 %*	*23.3 %*	*19.6 %*	*7.7 %*
YoY % Growth - Organic	*2.6 %*	*0.6 %*	*9.6 %*	*5.2 %*	*6.9 %*	*10.8 %*	*23.6 %*	*20.7 %*	*15.1 %*	*0.7 %*
YoY % Growth - Acquisitions	*5.2 %*	*(0.1)%*	*(3.2)%*	*(5.8)%*	*(5.2)%*	*— %*	*2.8 %*	*4.4 %*	*5.8 %*	*7.7 %*
YoY % Growth - FX	*(0.1)%*	*0.1 %*	*0.4 %*	*0.7 %*	*0.1 %*	*(0.3)%*	*(1.0)%*	*(1.8)%*	*(1.3)%*	*(0.6)%*
Income (Loss) from Operations	**$ 5.0**	**$ 1.4**	**$ 11.4**	**$ 4.0**	**$ (3.1)**	**$ 0.7**	**$ (86.6)**	**$ (3.3)**	**$ (2.2)**	**$ (6.7)**
Amortization	13.7	13.7	13.7	13.5	13.7	13.9	14.7	15.3	17.0	17.3
Depreciation - core	3.7	3.6	4.1	4.1	3.6	3.9	3.7	3.5	3.5	2.6
Depreciation - Mirion Business Combination step-up	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
Stock compensation	0.3	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.1
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	—	—	—	0.9
Goodwill impairment	—	—	—	—	—	—	87.3	—	—	—
Non-operating expenses	1.4	0.4	0.7	0.6	6.7	0.6	5.4	3.8	2.1	3.2
Other income/expense	(0.2)	—	—	(0.1)	—	—	(0.4)	(0.1)	0.4	—
Adjusted EBITDA	**$ 25.1**	**$ 20.5**	**$ 31.3**	**$ 23.5**	**$ 22.3**	**$ 20.4**	**$ 25.4**	**$ 20.4**	**$ 22.2**	**$ 18.6**
Income from operations margin	*6.8 %*	*2.0 %*	*14.0 %*	*5.8 %*	*(4.6)%*	*1.1 %*	*(113.8)%*	*(4.8)%*	*(3.3)%*	*(11.1)%*
Adjusted EBITDA margin	*34.3 %*	*30.7 %*	*38.5 %*	*34.2 %*	*32.8 %*	*30.7 %*	*33.4 %*	*29.7 %*	*33.2 %*	*30.9 %*

Ten Quarter Segment Reconciliation

Technologies

	Successor									
($ in millions)	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	**$ 133.9**	**$ 125.8**	**$ 149.1**	**$ 122.4**	**$ 129.2**	**$ 115.7**	**$ 141.8**	**$ 92.2**	**$ 109.0**	**$ 103.1**
YoY % Growth - Total	*3.7 %*	*8.7 %*	*5.1 %*	*32.8 %*	*18.5 %*	*12.2 %*	*17.9 %*	*(0.1)%*	*(14.7)%*	*(10.2)%*
YoY % Growth - Organic	*4.1 %*	*8.4 %*	*3.0 %*	*26.3 %*	*9.3 %*	*6.1 %*	*16.8 %*	*2.0 %*	*(9.0)%*	*(6.6)%*
YoY % Growth - Acquisitions	*— %*	*— %*	*— %*	*2.7 %*	*8.2 %*	*9.1 %*	*8.2 %*	*6.0 %*	*— %*	*— %*
YoY % Growth - FX	*(0.4)%*	*0.3 %*	*2.1 %*	*3.8 %*	*1.0 %*	*(3.0)%*	*(7.1)%*	*(8.1)%*	*(5.7)%*	*(3.6)%*
Income (Loss) from Operations	**$ 18.5**	**$ 12.6**	**$ 22.3**	**$ 5.4**	**$ 12.8**	**$ 5.5**	**$ (50.8)**	**$ (3.3)**	**$ (46.5)**	**$ (2.5)**
Amortization	17.3	17.8	18.1	19.2	19.5	19.7	19.6	19.9	20.5	21.5
Depreciation - core	2.0	2.1	2.4	2.2	2.2	2.2	2.3	2.1	1.9	1.9
Depreciation - Mirion Business Combination step-up	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.4	0.4
Stock compensation	0.4	0.4	0.5	0.3	0.3	0.2	0.3	0.3	0.3	0.1
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	—	—	—	5.4
Goodwill impairment	—	—	—	—	—	—	69.3	—	55.2	—
Non-operating expenses	0.4	—	0.2	0.3	0.2	0.6	1.9	0.8	1.2	1.1
Other income/expense	(0.1)	(0.1)	0.1	—	(0.1)	—	(0.1)	0.1	—	—
Adjusted EBITDA	**$ 38.9**	**$ 33.1**	**$ 44.0**	**$ 27.7**	**$ 35.2**	**$ 28.5**	**$ 42.8**	**$ 20.2**	**$ 33.0**	**$ 27.9**
Income from operations margin	*13.8 %*	*10.0 %*	*15.0 %*	*4.4 %*	*9.9 %*	*4.8 %*	*(35.8)%*	*(3.6)%*	*(42.7)%*	*(2.4)%*
Adjusted EBITDA margin	*29.1 %*	*26.3 %*	*29.5 %*	*22.6 %*	*27.2 %*	*24.6 %*	*30.2 %*	*21.9 %*	*30.3 %*	*27.1 %*

Ten Quarter Segment Reconciliation

Corporate & Other

	Successor									
($ in millions)	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —
Income (Loss) from Operations	$ (21.2)	$ (18.9)	$ (20.3)	$ (20.5)	$ (20.3)	$ (19.8)	$ (24.5)	$ (21.0)	$ (25.9)	$ (24.4)
Amortization	—	—	—	—	—	—	—	—	—	—
Depreciation - core	0.2	—	0.1	—	0.2	0.1	0.3	0.2	0.2	0.1
Depreciation - Mirion Business Combination step-up	—	0.1	—	0.1	0.1	0.1	—	0.1	0.1	—
Stock compensation	3.3	3.0	3.5	5.6	5.5	5.3	6.5	8.1	8.0	7.6
Goodwill impairment	—	—	—	—	—	—	—	—	—	—
Non-operating expenses	2.5	1.7	2.5	2.7	1.2	1.9	5.7	2.5	5.0	5.1
Other income/expense	—	—	(0.1)	(0.3)	0.1	0.1	—	0.2	(0.1)	—
Adjusted EBITDA	$ (15.2)	$ (14.1)	$ (14.3)	$ (12.4)	$ (13.2)	$ (12.3)	$ (12.0)	$ (9.8)	$ (12.6)	$ (11.6)
Income from operations margin	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
Adjusted EBITDA margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Ten Quarter Segment Reconciliation

Consolidated

	Successor									
($ in millions)	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	**$ 207.1**	**$ 192.6**	**$ 230.4**	**$ 191.2**	**$ 197.2**	**$ 182.1**	**$ 217.9**	**$ 160.9**	**$ 175.8**	**$ 163.2**
YoY % Growth - Total	*5.0 %*	*5.8 %*	*5.7 %*	*18.8 %*	*12.2 %*	*11.6 %*	*20.5 %*	*8.7 %*	*(4.3)%*	*(4.3)%*
YoY % Growth - Organic	*3.6 %*	*5.5 %*	*5.3 %*	*17.3 %*	*8.4 %*	*7.9 %*	*19.1 %*	*9.0 %*	*(1.7)%*	*(4.2)%*
YoY % Growth - Acquisitions	*1.8 %*	*— %*	*(1.1)%*	*(1.0)%*	*3.1 %*	*5.7 %*	*6.4 %*	*5.4 %*	*1.8 %*	*2.5 %*
YoY % Growth - FX	*(0.4)%*	*0.3 %*	*1.5 %*	*2.5 %*	*0.7 %*	*(2.0)%*	*(5.0)%*	*(5.7)%*	*(4.4)%*	*(2.6)%*
Income (Loss) from Operations	**$ 2.3**	**$ (4.9)**	**$ 13.4**	**$ (11.1)**	**$ (10.6)**	**$ (13.6)**	**$ (161.9)**	**$ (27.6)**	**$ (74.6)**	**$ (33.6)**
Amortization	31.0	31.5	31.8	32.7	33.2	33.6	34.3	35.2	37.5	38.8
Depreciation - core	5.9	5.7	6.6	6.3	6.0	6.2	6.3	5.8	5.6	4.6
Depreciation - Mirion Business Combination step-up	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.6	1.7	1.6
Stock compensation	4.0	3.6	4.2	6.1	6.0	5.6	7.0	8.5	8.5	7.8
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	—	—	—	6.3
Goodwill impairment	—	—	—	—	—	—	156.6	—	55.2	—
Non-operating expenses	4.3	2.1	3.4	3.6	8.1	3.1	13.0	7.1	8.4	9.4
Other income/expense	(0.3)	(0.1)	—	(0.4)	—	0.1	(0.4)	0.2	0.3	—
Adjusted EBITDA	**$ 48.8**	**$ 39.5**	**$ 61.0**	**$ 38.8**	**$ 44.3**	**$ 36.6**	**$ 56.4**	**$ 30.8**	**$ 42.6**	**$ 34.9**
Income from operations margin	*1.1 %*	*(2.5)%*	*5.8 %*	*(5.8)%*	*(5.4)%*	*(7.5)%*	*(74.3)%*	*(17.2)%*	*(42.4)%*	*(20.6)%*
Adjusted EBITDA margin	*23.6 %*	*20.5 %*	*26.5 %*	*20.3 %*	*22.5 %*	*20.1 %*	*25.9 %*	*19.1 %*	*24.2 %*	*21.4 %*

Non-GAAP Reconciliations

Consolidated – Income from Operations, Gross Profit & Adjusted EBITDA

($ in millions)	Three Months Ended June 30, 2024		Three Months Ended June 30, 2023	
GAAP Net Loss	**$**	**(12.0)**	**$**	**(28.4)**
Interest expense, net		13.1		13.6
Income tax expense (benefit) provision		0.7		(1.2)
Foreign currency (gain) loss, net		0.3		(0.3)
Change in fair value of warrant liabilities		(0.4)		5.7
Non-operating expenses		0.3		—
Other income/expense		0.3		(0.1)
Income (Loss) from Operations	**$**	**2.3**	**$**	**(10.6)**
Amortization	$	31.0	$	33.2
Depreciation		7.5		7.6
Stock compensation expense		4.0		6.0
Non-operating expenses		4.3		8.1
Other income/expense		(0.3)		—
Adjusted EBITDA	**$**	**48.8**	**$**	**44.3**
Gross Profit	**$**	**97.4**	**$**	**88.0**
Amortization		6.8		6.8
Depreciation		5.5		4.8
Non-operating expenses		0.5		0.3
Adjusted Gross Profit	**$**	**110.2**	**$**	**99.9**
Adjusted Gross Profit margin		*53.2 %*		*50.7 %*

Non-GAAP Reconciliations

Adjusted Earnings per Share

($ in millions)	Three Months Ended June 30, 2024	Three Months Ended June 30, 2023
Net loss attributable to Mirion Technologies, Inc. stockholders	**$ (11.7)**	**$ (27.7)**
Loss attributable to noncontrolling interests	(0.3)	(0.7)
GAAP Net Loss	**(12.0)**	**(28.4)**
Foreign currency (gain) loss, net	0.3	(0.2)
Amortization of acquired intangibles	31.0	33.2
Stock based compensation	4.0	6.0
Change in fair value of warrant liabilities	(0.4)	5.7
Non-operating expenses	4.6	8.0
Tax impact of adjustments above	(8.1)	(8.8)
Adjusted Net Income	**$ 19.4**	**$ 15.5**
Weighted average common shares outstanding — basic and diluted	**202.197**	**199.181**
Dilutive Potential Common Shares - RSU's	0.808	0.264
Adjusted weighted average common shares — diluted	**203.005**	**199.445**
Net loss per common share attributable to Mirion Technologies, Inc.	**$ (0.06)**	**$ (0.14)**
Adjusted EPS	**$ 0.10**	**$ 0.08**

Non-GAAP Reconciliations

Adjusted Order Growth (Decline)

	a		*b*		*a - b = c*		*c / b = d*
($ in millions)	**Three Months Ended June 30, 2024**		**Three Months Ended June 30, 2023**		**Variance ($)**		**Variance (%)**
Total Orders	$	205.1	$	207.0	$	(1.9)	-0.9%
Adjustment for ec[2] Acquisition		(2.7)		-			
Adjustment for MBD Reversal		7.1		9.8			
Adjusted Orders	**$**	**209.5**	**$**	**216.8**	**$**	**(7.3)**	**-3.4%**

Share Count Details[1]

Share Description	Outstanding Securities[2]	Notes
Outstanding Shares of Class A Common Stock (as of 6/30/2024)	**206,609,792**	▪ **Outstanding shares as of close of trading on the New York Stock Exchange (NYSE) June 30, 2024**
Shares of Class B Common Stock – Mirion Management[3] (as of 6/30/2024)	6,858,290	▪ Shares of Class B common stock are owned by certain current and former members of Mirion's management team and are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co, Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one-basis or cash based on a trailing stock price average.
Shares of Class A Common Stock – Founder Shares to vest at $12 per share	6,250,000	▪ A total of 18,750,000 founders shares vest in three equal tranches, based on the VWAP of our Class A common stock being greater than or equal to $12.00, $14.00 and $16.00 per share for any 20 trading days in any 30 consecutive trading day period, and such shares will be forfeited to us for no consideration if they fail to vest by October 20, 2026.
Shares of Class A Common Stock – Founder Shares to vest at $14 per share	6,250,000	
Shares of Class A Common Stock – Founder Shares to vest at $16 per share	6,250,000	
Illustrative Total Shares Outstanding	**232,218,082**	
Outstanding Equity Awards[4] (as of 6/30/2024)	2,972,299	▪ Mirion had 1.8 million shares of restricted stock units and 1.2 million shares of performance stock units outstanding as of June 30, 2024. Additionally, Mirion had reserved an additional 34.4 million shares of Class A common stock for future equity awards issuance under its 2021 Omnibus Incentive Plan (subject to annual automatic increases) as of June 30, 2024.
Total Illustrative Fully Diluted Shares	**235,190,381**	

1) All data on this slide is as of June 30, 2024, unless otherwise noted. All share numbers and dollar amounts are subject to adjustment for stock splits or other similar events.
2) This slide illustrates Mirion's outstanding and fully diluted shares based on certain assumptions set forth in the "Notes' column and is designed to be illustrative and provide investors with additional information only. Different assumptions will yield different results, and the actual number of our fully diluted shares in the future may differ significantly from those based on these assumptions. As a result, you should not rely on these forward-looking statements as predictions of future events. The information provided is not presented in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share (ASC 260) and does not represent a computation of weighted average shares nor are the numbers appropriate for calculating Basic or Diluted EPS under ASC 260.
3) The slide illustrates the assumption that all of the paired interests will be redeemed and exchanged for shares of Class A common stock.
4) The number of reserved shares are subject to automatic increases on the first day of each year in an amount equal to the lesser of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately preceding year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by Mirion Compensation Committee in its discretion.

Footnotes to Share Count and Adjusted Metrics

Share Count

206,609,792 shares of Class A common stock were outstanding as of June 30, 2024. This excludes (1) 6,858,290 shares of Class B common stock outstanding as of June 30, 2024 (2) 18,750,000 founder shares which are shares of Class A common stock subject to vesting in three equal tranches, based on the volume-weighted average price of our Class A common stock being greater than or equal to $12.00, $14.00 and $16.00 per share for any 20 trading days in any 30 consecutive trading day period, and such shares will be forfeited to us if they fail to vest by October 20, 2026; (3) 1.8 million shares of Class A common stock underlying restricted stock units and 1.2 million shares of Class A common stock underlying performance stock units; and (4) any other shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 34,369,922 shares reserved (subject to annual automatic increases) as of June 30, 2024. The 6,858,290 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of June 30, 2024, unless otherwise noted.

Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Organic Revenues is defined as revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.

Adjusted Gross Profit is defined as gross profit adjusted to exclude the impact of amortization of acquired intangible assets, depreciation, the impact of purchase accounting on the recognition of deferred revenue and certain non-operating expenses (certain purchase accounting impacts related to inventory and costs to achieve operational synergies).

Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, the impact of purchase accounting on the recognition of deferred revenue, certain non-operating expenses (including impairment of an equity investment, incremental one-time costs related to the Business Combination, incremental one-time costs associated with becoming a public company, mergers, acquisition and divestiture expenses, restructuring costs, costs to achieve information technology system integration and efficiency, and costs to achieve integration and operational synergies), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted Net Income is defined as net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, the impact of purchase accounting on the recognition of deferred revenue, changes in the fair value of warrants and certain non-operating expenses also excluded from Adjusted EBITDA, stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted EPS is as adjusted net (loss) income divided by weighted average common shares outstanding — basic and diluted.

Adjusted Free Cash Flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses described above. We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities.

Free Cash Flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts.

Net Leverage is defined as net debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start of the applicable period.

Operating Metrics

Orders and Order Growth is defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior period. Foreign exchange rates are based on the applicable rates as reported for the time period.

Adjusted Order Growth (Decline) is defined as order growth (decline) adjusted to exclude the impact of acquisitions and divestitures.

MIRION